D Girard

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

Agnès Girard, D Girard, A. R. English et al. · Antimicrobial Agents and Chemotherapy · 1987 · 321 citations

Immunology, Pharmacotherapy, Antimicrobial Chemotherapy +18

Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides.

G. Michael Bright, A. Nagel, Jon Bordner et al. · The Journal of Antibiotics · 1988 · 237 citations · Full text

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

Thomas D. Gootz, Richard P. Zaniewski, S L Haskell et al. · Antimicrobial Agents and Chemotherapy · 1996 · 134 citations · Full text

S. Pneumoniae, Antimicrobial Chemotherapy, Antibiotic Resistance +17

Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo

James A. Retsema, Agnès Girard, D Girard et al. · Journal of Antimicrobial Chemotherapy · 1990 · 74 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +14

Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection

Agnès Girard, D Girard, James A. Retsema · Journal of Antimicrobial Chemotherapy · 1990 · 72 citations